Wanbury Is Quietly Fixing Its Balance Sheet — And Delivering 154% PAT Growth While At It

💊 CMP: ₹281.00 | 🔼 Up 1.22% | NSE: WANBURY | BSE: 524212

🧠 At a Glance

Wanbury Ltd, a mid-cap pharma player you’ve probably ignored, just dropped a stunner of a quarter.

• PAT up 154% YoY
• EBITDA up 65%
• Revenue up 23%
• Debt refinanced from 21% to 12.5%
• Two new products launched
• Zero-observation Brazil FDA (ANVISA) clearance

All while juggling a 40-day plant shutdown for upgrades.

Forget your usual pharma darlings. Wanbury is operating in stealth mode — cleaning up, scaling up, and paying off toxic debt.

🏭 About the Company

• 👨🔬 Founded in 1988, HQ in Navi Mumbai
• 📦 Two Plants: Tanuku (Andhra) + Patalganga (Maharashtra)
• 🌍 Export Footprint: 50+ countries
• 🧪 Focus Areas:
  • APIs (Metformin, Sertraline, Tramadol, etc.)
  • Branded Generics in Gynae, Ortho, GI, Nutraceuticals
• 🏥 Clients: Major Indian and global generics players
• 👨⚕️ Recent Leadership Additions:
  • Rashesh Patel (Corporate Director – India Formulations)
  • Two new Independent Directors onboard

📊 Q4 FY25 Performance (Consolidated)